K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 6.17 CAD 0.33% Market Closed
Market Cap: 614m CAD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+25%
Revenue
Forecast
+5%
Operating Income
Forecast
N/A
Net Income
Forecast
+23%

Wall Street
Price Targets

GUD Price Targets Summary
Knight Therapeutics Inc

Wall Street analysts forecast GUD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GUD is 7.71 CAD with a low forecast of 6.51 CAD and a high forecast of 9.45 CAD.

GUD Lowest Forecast
Wall Street Target
6.51 CAD
6% Upside
GUD Average Forecast
Wall Street Target
7.71 CAD
25% Upside
GUD Highest Forecast
Wall Street Target
9.45 CAD
53% Upside
Lowest
Price Target
6.51 CAD
6% Upside
Average
Price Target
7.71 CAD
25% Upside
Highest
Price Target
9.45 CAD
53% Upside
Knight Therapeutics Inc Competitors:
Price Targets
JUBLPHARMA
Jubilant Pharmova Ltd
47% Upside
COPN
Cosmo Pharmaceuticals NV
81% Upside
AUROPHARMA
Aurobindo Pharma Ltd
30% Upside
4523
Eisai Co Ltd
47% Upside
JUBLPHARMA
Jubilant Pharmova Ltd
47% Upside
COPN
Cosmo Pharmaceuticals NV
81% Upside
AUROPHARMA
Aurobindo Pharma Ltd
30% Upside
4523
Eisai Co Ltd
47% Upside
S
002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
35% Downside

Revenue
Forecast

Revenue Estimate
Knight Therapeutics Inc

For the last 8 years the compound annual growth rate for Knight Therapeutics Inc's revenue is 68%. The projected CAGR for the next 3 years is 5%.

68%
Past Growth
5%
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Knight Therapeutics Inc

The compound annual growth rate of Knight Therapeutics Inc's operating income for the next 2 years is 107%.

N/A
Past Growth
107%
Estimated Growth
Estimates Accuracy
72%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Knight Therapeutics Inc

For the last 8 years the compound annual growth rate for Knight Therapeutics Inc's net income is -17%. The projected CAGR for the next 3 years is 23%.

-17%
Past Growth
23%
Estimated Growth
Estimates Accuracy
45%
Average Beat
What are analyst estimates?

See Also

Summary
GUD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GUD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GUD stock valuation using valuation multiples.
Wall Street Estimates
GUD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GUD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GUD's stock price target?
Price Target
7.71 CAD

According to Wall Street analysts, the average 1-year price target for GUD is 7.71 CAD with a low forecast of 6.51 CAD and a high forecast of 9.45 CAD.

What is Knight Therapeutics Inc's Revenue forecast?
Projected CAGR
5%

For the last 8 years the compound annual growth rate for Knight Therapeutics Inc's revenue is 68%. The projected CAGR for the next 3 years is 5%.

What is Knight Therapeutics Inc's Operating Income forecast?
Projected CAGR
107%

The compound annual growth rate of Knight Therapeutics Inc's operating income for the next 2 years is 107%.

What is Knight Therapeutics Inc's Net Income forecast?
Projected CAGR
23%

For the last 8 years the compound annual growth rate for Knight Therapeutics Inc's net income is -17%. The projected CAGR for the next 3 years is 23%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 243,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.